Cramer's Skepticism on Pfizer: High Dividend Not Enough to Win Over Analyst

Unpacking Cramer's Caution: Why Pfizer's 7% Dividend Fails to Impress

A Closer Look at Analyst's Concerns

During a recent broadcast of CNBC's "Mad Money," financial personality Jim Cramer expressed his reluctance to endorse Pfizer, even though the pharmaceutical firm boasts a substantial 7% dividend yield and its shares are hovering near their annual low. A caller from Orland Park, Illinois, attempted to present Pfizer as a compelling opportunity for both income and value, acknowledging the stock's tempting attributes. However, Cramer ultimately opted to pass, explaining his struggle to identify clear avenues for the company's future expansion.

The Inquiry and Its Context

Following a lighthearted preamble with the host, the caller straightforwardly inquired about Pfizer, highlighting its status as a pharmaceutical company whose CEO has frequently appeared on Cramer's program, its attractive dividend, and its current low stock price. Such a proposition typically garners a more favorable response, especially given the CEO Albert Bourla's repeated presence on the show.

Cramer's Rationale Behind His Pfizer Assessment

Pfizer, trading under the ticker NYSE:PFE, received a diagnostic evaluation rather than an endorsement from Cramer. He pointed out the company's persistent issues with earnings growth, noting that the acquisition of Seagen hadn't yielded the anticipated results. While acknowledging the safety of the 7% dividend, Cramer highlighted a 59% decline in Comirnaty sales and a 63% operational decrease in Paxlovid, despite the 2023 Seagen deal, valued at approximately $43 billion, being intended to bolster Pfizer's oncology portfolio post-COVID. Although one of Seagen's assets, Padcev, saw a 39% operational increase in Q1 2026, it was insufficient to offset the significant downturn in other key products.

Despite these challenges, Pfizer's overall financial reports still indicate a company that largely meets or exceeds expectations. In the first quarter of 2026, Pfizer reported revenues of $14.45 billion, surpassing the estimated $13.80 billion, and achieved an adjusted EPS of $0.75, marking its fifth consecutive beat. The company also reiterated its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and an adjusted EPS of $2.80 to $3.00, as per its 8-K filing. However, net income saw a 9.44% year-over-year decrease to $2.687 billion, with operating income falling by 31.44%. These figures underscore the growth deficit that Cramer pinpointed.

The Fundamental Conflict: Steady Income Versus Absent Growth

Cramer's position rests on the premise that a secure dividend alone isn't enough to justify an investment. Pfizer's quarterly dividend of $0.43, increased from $0.42 in January 2026, continues a trend of modest increases. The company paid out $9.8 billion in dividends for fiscal year 2025 and has indicated no share buybacks for 2026, despite a remaining $3.3 billion authorization. Capital is being allocated to dividends and strategic acquisitions, such as the approximately $7.0 billion Metsera deal in the obesity/GLP-1 sector and a $1.35 billion in-licensing agreement for a PD-1 x VEGF bispecific from 3SBio. While these investments aim to replenish the pipeline, they haven't yet significantly influenced earnings in a manner that satisfies Cramer.

Current Market Sentiment Towards Pfizer

The market's reaction appears to echo Cramer's skepticism, at least for the present. Pfizer closed at $24.05 on July 8, having dropped 6.13% over the preceding month and remaining relatively unchanged year-to-date. Its 52-week trading range spans from $21.97 to $28.28, with a trailing yield of 7.25%. The analyst consensus target is $29.00, with a majority of 16 'Hold' ratings. A forward Price-to-Earnings (P/E) ratio of 8x suggests that the market is already factoring in concerns such as the impending patent cliffs for Eliquis and Vyndaqel, the impact of the IRA Medicare Part D redesign, and the risks associated with Most-Favored-Nation drug pricing policies.

For investors comparing Pfizer with other high-yield equities, our ongoing Paycheck Portfolio series offers insights into how income investors are navigating the complexities of yield traps versus consistently performing dividend payers in 2026.

Concluding Thoughts on Pfizer's Investment Case

Cramer's perspective is his own, offering one view on Pfizer. Income-focused investors, primarily concerned with a stable 7% payout, might reasonably interpret the same data and arrive at a different conclusion, particularly with the stock trading near the lower end of its 52-week range. Conversely, growth investors seeking a catalyst will clearly understand Cramer's reservations. This report serves to convey his opinion, and readers should treat it as such. It is crucial to conduct personal due diligence before making any investment decisions